Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flavitan is a brand name for riboflavin butyrate, a long-acting derivative of riboflavin (vitamin B2) developed and marketed by TOA Eiyo. It is primarily used in Japan for the treatment of hyperlipidemia, specifically hypercholesterolemia, and for the prevention and treatment of vitamin B2 deficiency. As a butyric acid ester of riboflavin, it is more lipid-soluble than standard riboflavin, allowing for more sustained blood and tissue levels. The drug functions by serving as a precursor to the coenzymes flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN), which are essential for lipid metabolism and the reduction of serum cholesterol and triglyceride levels. It is also indicated for improving lipid metabolism in patients with arteriosclerosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on riboflavin butyrate.